Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).

Kim A PappA MenterC LeonardiJ SoungS WeissR PillaiA Jacobson

Published in: The British journal of dermatology (2020)

These findings indicate that brodalumab is efficacious and safe for continuous long-term treatment of psoriasis, and support the potential for response after discontinuation and retreatment.

Keyphrases

phase iii
open label
clinical trial
phase ii
double blind
placebo controlled
study protocol
atopic dermatitis
randomized controlled trial
human health
climate change
combination therapy
risk assessment